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Abstract
Cell replacement therapies in Parkinson’s disease (PD)
aim to provide long-lasting relief of patients’
symptoms. Previous clinical trials using transplantation
of human fetal ventral mesencephalic (hfVM) tissue in
the striata of PD patients have provided proof-of-
principle that such grafts can restore striatal
dopaminergic (DA-ergic) function. The transplants
survive, reinnervate the striatum, and generate
adequate symptomatic relief in some patients for
more than a decade following operation. However,
the initial clinical trials lacked homogeneity of
outcomes and were hindered by the development of
troublesome graft-induced dyskinesias in a subgroup
of patients. Although recent knowledge has provided
insights for overcoming these obstacles, it is unlikely
that transplantation of hfVM tissue will become
routine treatment for PD owing to problems with
tissue availability and standardization of the grafts.
The main focus now is on producing DA-ergic
neuroblasts for transplantation from stem cells (SCs).
There is a range of emerging sources of SCs for
generating a DA-ergic fate in vitro. However, the
translation of these efforts in vivo currently lacks
efficacy and sustainability. A successful, clinically
competitive SC therapy in PD needs to produce long-
lasting symptomatic relief without side effects while
counteracting PD progression.
Introduction
Parkinson’s disease (PD) is a common neurodegenenera-
tive disorder characterized by the classical motor symp-
toms of bradykinesia, rigidity and tremor. The
pathological hallmark of PD is a gradual loss of nigos-
triatal dopamine (DA) neurons, but neuronal
degeneration also occurs in non-DA-ergic systems [1].
Treatments aiming to relieve PD motor symptoms
include the use of oral preparations of L-3,4-dihydroxy-
phenylalanine (L-DOPA) and DA receptor agonists and,
in more advanced cases, the use of apomorphine, deliv-
ery of L-DOPA through continuous intestinal adminis-
tration, and deep brain stimulation in subthalamic
nucleus and globus pallidus via surgically implanted
electrodes. These treatments have proved effective to a
point, but they can generate adverse effects, such as L-
DOPA-induced dyskinesias, and they do not counteract
the progression of the disease.
Series of studies in PD patients with intrastriatal grafts
of human fetal ventral mesencephalic (hfVM) tissue
have provided proof-of-principle that cell therapy can
work in PD patients, that is, that the dead DA neurons
can be replaced by new neurons by transplantation
[2-5]. The grafts can provide DA-ergic reinnervation of
the striatum and symptomatic relief lasting as long as
16 years following transplantation in some patients [2-5]
(Figure 1). The most successful operated cases were able
to withdraw from L-DOPA therapy. Although some
results were promising, the outcomes across the differ-
ent clinical trials using hfVM tissue have been inconsis-
tent. In addition, the further development of this
approach was hindered by the occurrence of adverse
effects, so-called graft-induced dyskinesias (GIDs), in a
subgroup of patients [6-8]. Even if new, optimized pro-
tocols would improve the safety and efficacy in future
hfVM tissue trials, it is doubtful whether transplantation
of hfVM tissue will become a mainstream treatment for
PD due to shortcomings with tissue availability and
standardization of the grafts. In this respect, stem cells
(SCs) could provide an unlimited source of well-charac-
terized DA neurons for transplantation and therefore
overcome these issues (Figure 2). Here, we aim to dis-
cuss what we learned from clinical research with hfVM
tissue and also review the current status of SC therapy
in PD.* Correspondence: marios.politis@imperial.ac.uk1Centre for Neuroscience, Department of Medicine, Imperial College London,
Hammersmith Hospital, DuCane Road, London W12 0NN, UK
Full list of author information is available at the end of the article
Politis and Lindvall BMC Medicine 2012, 10:1
http://www.biomedcentral.com/1741-7015/10/1
© 2012 Politis and Lindvall; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lessons learned from hfVM tissue clinical trials
Short- and long-term follow-up studies on PD patients
subjected to hfVM tissue transplantation have indicated
ways of improving the safety and efficacy in future
human cell therapy trials. The correct selection of PD
patients entering these trials will be of major impor-
tance. Positron emission tomography (PET) studies have
indicated that the PD patients with the best functional
outcome after intrastriatal transplantation of hfVM tis-
sue were the ones in whom the DA-ergic denervation
Figure 1 Human fetal ventral mesencephalic tissue grafts provide long-lasting major relief of motor symptoms (reductions in UPDRS
motor scores) and restore dopamine innervation (increases in 18F-DOPA PET uptake) in the grafted striatum in Patients 7 (A) and 15
(B) from the Lund series (modified figure from [4]). Patient 7 and Patient 15 stopped receiving any form of dopaminergic medication four
and five years following operation, respectively. PET = Positron emission tomography; UPDRS = Unified Parkinson’s Disease Rating Scale.
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preoperatively was restricted to the dorsal parts of the
striatum [9,10]. Based on these findings, PD patients
with more widespread preoperative DA-ergic denerva-
tion, including the ventral striatum, should probably be
excluded from these trials, as the predictive outcome
would be modest or no clinical benefit.
An important breakthrough was the unveiling of one
important mechanism underlying GIDs. Studies utilizing
PET and clinical observations in previously transplanted
PD patients provided strong evidence that GIDs were
caused by a graft-derived striatal serotonergic hyperin-
nervation, possibly engaging in false DA release, which
was also weighted by an unfavorable serotonin/DA
transporter ratio [4,5,11]. Interestingly, the occurrence
of GIDs shows a slow and gradual increase compared to
the rapid improvement of motor symptoms following
transplantation. This difference is likely due to interac-
tions of serotonin and DA neuronal transmissions
because of the gradual expansion of graft-derived sero-
tonergic innervation that takes a leading role in regulat-
ing synaptic DA levels in the reinnervated areas
[5,12,13].
These findings suggested strategies for avoiding the
development of GIDs following DA cell therapy with
hfVM tissue or SCs in PD. HfVM tissue contains both
dopaminergic and serotonergic neuroblasts [14] and the
dissection of hfVM tissue should, therefore, be per-
formed in a way to minimize the serotonergic compo-
nent. Also, when producing DA neurons from SCs,
serotonergic neurons should be kept to a minimum or
removed by cell sorting. Moreover, culture and storage
of the tissue prior to transplantation could change its
composition in favor of non-DA-ergic cells [15]. In
accordance, previous studies have reported an increased
prevalence of GIDs in patients who received tissue that
had been stored for long periods compared to those
who received fresh tissue [6,7]. Alternatively, GIDs
could be effectively suppressed with systemic adminis-
tration of serotonin 1A agonists, which dampen trans-
mitter release from serotonergic neurons [4,5,11].
Stem cell therapy in Parkinson’s disease
It remains to be shown whether SC-derived DA neurons
can efficiently reinnervate the striatum and provide
functional recovery in PD patients. Knowledge from
hfVM tissue transplantation in animals and humans has
provided a number of requirements for establishing a
clinically competitive SC-based therapy in PD. The SC
grafts should (a) exhibit a regulated release of DA and
molecular, electrophysiological, and morphological prop-
erties similar to those of substantia nigra neurons
[16,17]; (b) enable survival of more than 100,000 DA
neurons per human putamen [18]; (c) reestablish the
DA network within the striatum and restore the func-
tional connectivity with host extra-striatal neural circui-
tries [19]; (d) reverse the motor deficits resembling
human symptoms in animal models of PD and induce
long-lasting and major symptomatic relief in PD
patients; and (e) produce no adverse-effects such as
tumor formation, immune reactions and GIDs.
To date, only a few steps have been established
towards these goals in vivo. The in vitro generation of
SC-derived cells having DA-ergic properties from fetal
brain and embryonic SCs (ESCs) and from bone marrow
Figure 2 Schematic illustration of possible sources of stem cells for therapy in Parkinson’s disease. 1) Neural stem cells (NSCs) from
human fetal brain, expanded and differentiated to DA-ergic neurons; 2) Pluripotent cells generated from blastocysts (ESCs) or fibroblasts (iPSCs),
expanded and differentiated to DA-ergic neurons; 3) DA-ergic neurons generated by direct conversion of fibroblasts; 4) Bone marrow-derived
mesenchymal stem cells (MSCs).
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SCs has already been shown [20-22] (Figure 2). How-
ever, it is unclear whether these cells having DA-ergic
properties can be used in PD patients. Table 1 sum-
marizes the advantages and disadvantages of different
stem cell types for use in PD.
ESCs are highly proliferative and retain pluripotency
after extended periods of in vitro expansion [23]. Since
they can give rise to any type of cell in the body includ-
ing DA-ergic neurons [24-26], their potential to be use-
ful in a clinical setting seems to be great. Rodent and
human ESC-derived DA-ergic neurons have been shown
to survive transplantation into the striatum of PD rats
and generate some degree of functional recovery
[27-30]. However, studies have shown that the survival
of ESC-derived DA-ergic neurons post-transplantation is
relatively low [27,28,31]. A major concern with using
ESC-derived DA-ergic neurons for transplantation in PD
patients is the risk of adverse effects such as tumor for-
mation which has been reported in rats [29,31]. Cell
sorting or prolonged differentiation and thereby exhaus-
tion of non-differentiated cell pools in vitro prior to
transplantation could potentially reduce the risk of
tumor formation [32].
Another promising source of SCs is adult fibroblasts
that are reprogrammed to so-called induced pluripotent
SCs (iPSCs) [33] and then differentiated to DA-ergic
neurons (Figure 2). The iPSC technology has raised the
possibility of generating an unlimited source of PD
patient-specific DA-ergic neurons, which theoretically
also could be used for autologous transplantation
[34-37]. DA-ergic neurons were first generated from
mouse iPSCs, transplanted into the striatum of a rat PD
model and shown to ameliorate functional deficits [36].
Recently, DA-ergic neurons were also produced from
iPSCs derived from fibroblasts in adult humans [38,39]
and PD patients [37,40]. Such neurons survived trans-
plantation into the striatum of PD rodents and pro-
duced some degree of functional recovery [39,40].
Potential advantages with the use of iPSCs are that PD
patient-specific DA neuroblasts could minimize the
immune reactions and eliminate the ethical issues asso-
ciated with the use of human ESCs. However, as with
ESCs, the risk for tumor formation needs to be mini-
mized before iPSC-derived DA-ergic neurons can be
considered as an option for transplantation in a clinical
setting in PD. Moreover, there are concerns about
whether the DA-ergic neurons delivered by autologous
transplantation in PD would be more susceptible to the
disease pathology because genetic mutations could also
be present in the fibroblast-derived cells [41,42].
Functional DA-ergic neurons with a substantia nigra
phenotype can now also be generated by directly repro-
gramming mouse and human fibroblasts by expressing
neural lineage-specific transcription factors [43-45] (Fig-
ure 2). This conversion does not occur through a pluri-
potent SC stage and thereby the risk of tumor
formation is eliminated. Before their clinical use in PD
is considered, it is necessary to show that the directly
Table 1 Advantages and disadvantages of different stem cell types for use in Parkinson’s disease
Stem Cell Type Definition Advantages Disadvantages
Embryonic Stem Cells
(ESCs)
Pluripotent stem cells derived from the inner cell
mass of the blastocyst that are able to differentiate
into cells of the three germ layers and show an
extensive capability for self-renewal without
differentiation, both in vivo and in vitro
(a) Highly proliferative/retain
pluripotency after in vitro
expansion
(b) Can generate DA-ergic
neurons
(c) Shown to survive
transplantation and generate
some degree of functional
recovery
(a) Risk of tumor formation
Induced pluripotent Stem
Cells (iPSCs)
Reprogrammed adult murine fibroblasts into ESC-like
cells
(a) Generation of unlimited PD
patient-specific cells/
autologous transplantation
(b) Shown to survive
transplantation and generate
some degree of functional
recovery
(c) Could minimize immune
reactions and ethical issues
Risk of tumor formation
(b) Autologous transplantation -
risk of susceptibility to the





Small population of cells in the bone marrow that
can differentiate into adipocytes, chondrocytes and
osteoblasts, both in vivo and in vitro
(a) Improve motor
performance in mice
(b) No adverse effects in
humans at 12 months
following transplantation
(a) Modest clinical improvement
in humans
Fetal brain neural Stem
Cells (NSCs)
Multipotent stem cells that are able to differentiate
into neurons, astrocytes and oligodendrocytes
(a) Lower risk of tumor
formation and immune
rejection than ESCs
(a) Shown only limited
differentiation in vivo
(b) Shown only partial effect in
PD-like symptoms
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converted DA-ergic neurons can survive transplantation
and give rise to substantial improvements in animal
models.
Fetal brain neural SC (NSC)-derived DA-ergic neurons
(Figure 2) are associated with lower risk of tumor for-
mation and immune rejection than ESCs [46]. Early stu-
dies reported that non-differentiated NSCs taken from a
human source and transplanted in rats have limited dif-
ferentiation in vivo and only partially affect PD-like
symptoms [47]. A more recent study showed that non-
differentiated NSCs implanted into PD primates sur-
vived, migrated, and had a functional impact [48]. A
small number of NSC progeny differentiated into DA
phenotypes. The use of developmental signals such as
sonic hedgehog, Wnt5a and others in fetal NSC differ-
entiation in vitro enhances the DA-ergic yield and mul-
tiple signals can have synergistic effects [49-54].
Production of fetal NSC-derived DA-ergic neurons
through well-controlled differentiation protocols in vitro
should ensure better homogeneity between grafts.
Bone marrow-derived stromal cells and mesenchymal
SCs (MSCs) have been proposed as potential cell
sources for transplantation in PD (Figure 2). It has been
reported that non-differentiated murine MSCs are able
to differentiate into tyrosine hydroxylase-positive neu-
rons and improve motor performance in mice [55].
Also, it has been demonstrated that cells with DA-ergic
properties can be produced from both rat and human
MSCs, and that transplantation of these cells gave rise
to improvement of motor function in an animal model
of PD [20]. More recently, a clinical trial in advanced
PD patients using unilateral transplantation of autolo-
gous bone marrow-derived MSCs into the sublateral
ventricular zone reported modest clinical improvement
with no adverse effects such as tumor formation at 12
months [56]. In this trial, there were no PET assess-
ments before and after transplantation in order to deter-
mine graft survival or changes of DA-ergic striatal
function [57]. Thus, the mechanisms underlying the
reported modest improvements are completely
unknown. Further preclinical work is needed for investi-
gating the ability of MSCs to differentiate into DA-ergic
neurons and to reverse functional deficits in animal
models.
Conclusions
Although the ability to restore function in PD patients
by DA-ergic neuron replacement has been demonstrated
to some extent with hfVM tissue, the focus is now on
producing standardized DA-ergic neuroblasts from SCs
for transplantation. ESCs and iPSCs seem the simplest
to manipulate towards a DA-ergic fate and to produce
large numbers of DA-ergic neurons in vitro, but fetal
brain NSCs could also be useful for clinical application.
Both iPSC-derived and directly converted DA-ergic neu-
rons have one more advantage as they potentially can be
used for autologous transplantation in PD patients.
Several important in vivo properties, which will be
decisive for the success or failure of a clinical trial in
PD, remain to be demonstrated for human SC-derived
DA-ergic neurons in animal models. These include the
ability of the SC-derived DA-ergic neurons to substan-
tially reinnervate striatum, restore DA release and mark-
edly improve PD symptoms. Before going ahead with
human trials using transplantation of SC-derived DA-
ergic neurons, the risks for tumor formation, immune
reactions, and development of GIDs need to be tested
and proven minimal. Major research efforts will be
needed for the development of a clinically competitive
SC-based therapy, which for the first time opens up the
possibility for an effective restorative treatment for PD
patients.
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